激素敏感寡转移性复发前列腺癌的随机II期试验:立体定向消融放疗联合度伐利尤单抗(POSTCARD GETUG P13)研究方案
该多中心随机II期研究方案拟在法国学术医院入组96例前列腺癌且转移灶不超过5个(淋巴结和/或骨)的患者,按2:1随机分为度伐利尤单抗联合SBRT组与单纯SBRT组,主要终点为2年无进展生存期,以评估联合治疗能否改善无进展生存。
要点
- 研究假设SBRT(3次分割)联合度伐利尤单抗可增强寡转移灶的免疫应答并改善无进展生存。
- 计划3年内入组96例前列腺癌且转移灶不超过5个(淋巴结和/或骨)的患者。
- 主要终点为2年无进展生存期,次要终点包括去势抵抗-free生存、生活质量、毒性、前列腺癌特异性生存、总生存和免疫应答。
核心结论
- 研究假设度伐利尤单抗将增强针对寡转移灶的SBRT后的免疫应答,目的是通过随机2:1的II期试验证明SBRT(3次分割)联合度伐利尤单抗较单纯SBRT改善转移灶不超过5个的激素敏感寡转移性前列腺癌患者的无进展生存。
研究设计与样本
- 多中心随机II期研究,在法国学术医院开展。
- 入组前列腺癌且转移灶不超过5个(淋巴结和/或骨)的患者,按2:1随机分为A组(试验组,度伐利尤单抗联合针对转移灶的SBRT)和B组(对照组,单纯针对转移灶的SBRT)。
- 计划3年内共入组96例患者。
主要发现
- 主要终点为2年无进展生存期。
- 次要终点包括去势抵抗-free生存、生活质量、毒性、前列腺癌特异性生存、总生存和免疫应答。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As in other solid tumors, increasing evidence indicates that patients diagnosed with a limited number of prostate cancer metastases, so-called oligometastases, have a better prognosis than patients with extensive metastatic disease. Stereotactic body radiotherapy (SBRT) is now considered an option in this population.Programmed death-1 (PD-1) and its ligands (PD-L1) are targeted by immune checkpoint inhibitors. Preclinical studies have shown that the tumor immune microenvironment changes when combining radiotherapy with immunotherapy, especially with hypofractionated radiotherapy.The oligometastatic setting appears to be the most relevant clinical situation for evaluating the immune response generated by radiotherapy and immune checkpoint inhibitors in patients with an intact immune system.We hypothesize that durvalumab will enhance the immune response following SBRT targeting oligometastatic lesions. Our purpose is to demonstrate, via a randomized 2:1 phase II trial, that SBRT (3 fractions) with durvalumab in oligometastatic hormone-sensitive prostate cancer patients would improve progression-free survival in patients with prostate cancer with up to 5 metastases compared to patients who exclusively received SBRT. METHODS: This is a multicentric randomized phase II study in French academic hospitals. Patients with prostate cancer and up to 5 metastases (lymph node and/or bone) were randomized into a 2:1 ratio between Arm A (experimental group), corresponding to durvalumab and SBRT to the metastases, and Arm B (control group), corresponding to SBRT alone to the metastases. The study aims to accrue a total of 96 patients within 3 years. The primary endpoint is two-year progression-free survival and secondary endpoints include androgen deprivation therapy-free survival, quality of life, toxicity, prostate cancer specific survival, overall survival, and immune response. DISCUSSION: The expected benefit for the patients in the experimental arm is longer life expectancy with acceptable toxicity. We also expect our study to provide data for better understanding the synergy between immunotherapy and radiotherapy in oligometastatic prostate cancer.
引用
- Rogé M, Pointreau Y, Sargos P, et al. Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol. Clin Transl Radiat Oncol. 2023. PMID: 36968576. doi:10.1016/j.ctro.2023.100613
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。